| | Home | Back To Index | |
|
|
Post Genome Project Era Proteomics R&D Competition January 2003 English or Japanese Version $1495.00. 159 Pages Executive Overview Proteomics is projected to grow from a $565 million market in 2001 to over $3.3 billion in 2006. This represents an average annual rate of growth of over 40%. The fastest growing segment of the proteomics market is expected to be the protein chip segment that will increase from $65.7 million in 2001 to over $723 million in 2006. This represents a 11-fold increase in market size in a six-year period and an average annual growth rate approaching 62%. Demand for proteomics services is expected to be strong throughout this time period with an average annual growth rate of over 50%. The rate of growth in this market segment is expected to slow after 2004 when next generation proteomics platforms are introduced. The proteomics platform market segment will remain the largest with a growth from $311 million in 2001 to approximately $1.7 billion in 2006. Following the release of the first full draft of the human genome, the spotlight in biomedical research is shifting from genomics to proteomics as the key technology to transform information into pharmaceutical products. The need to improve the speed and efficiency of drug discovery is the primary driver of proteomics. Current step-wise screening and chemical optimization methods are both time-consuming (averaging 10-12 years from discovery to market) and expensive (estimated costs range from $500M-$750M). In addition, there is a high rate of failure in the clinical trials process due to toxicity or low efficacy of selected drug targets resulting in an increased interest in identification of biomarkers suitable to use in therapeutic planning and individualized medicine. It is hoped that both the rate of drug development and the rate of discovery of novel, informative biomarkers will dramatically improve using emerging proteomics platforms. The use of proteomics capabilities has the potential to decrease overall spending per new chemical compound by approximately 30%, while decreasing the time investment by two years. The reality is that genomic technologies (use of DNA arrays and mRNA profiling) have resulted in a bottleneck in target validation. In order to realize the potential for efficiency, both genomics and proteomics need to be leveraged by applying these tools throughout validation to result in suitable and validated targets. This will require the construction of a systems biology framework to understand on a molecular level the disease mechanisms that often involve multiple targets and pathways. All major pharmaceutical companies are searching for ways of accelerating drug discoveries. An important strategy to increase efficiency and reduce attrition in discovery is the ability to develop new drugs in parallel with disease biomarkers. With decreasing numbers of drugs in the clinical pipeline, Pharma (the pharmaceutical industry) is actively evaluating methods to increase the return on their R&D dollars by raising R&D productivity. Proteomics offers a clearer path toward this than genomics for several reasons. First, the same proteomics platforms can be used to test multiple biochemical properties. When the same target screen positive in multiple tests, it increases confidence in the role of that target in the disease of interest. Second, proteomics targets the biomolecules responsible for disease directly while genomics measures the levels of the messages encoding them, an indirect measurement of correlation. Third, proteomics platforms that are used in R&D for discovering drug targets can also be used in upstream in both pre-clinical R&D and post-clinical development. For example, the same tests on proteomic chips are being applied to in drug discovery, target validation, biomarker studies and drug candidate evaluation. Similarly, the hybrid sample preparation/MS analysis platforms under active development by several proteomics platform providers can be used both in discovery and in screening all the way through manufacturing QC to test product purity. |
|
Table of Contents
2. THE MARKET OVERVIEW FOR PROTEOMICS IN PHARMACEUTICAL R&D
3. CURRENT PROTEOMICS MARKET PARTICIPANTS BY MARKET SEGMENT
4. DRIVERS OF PROTEOMICS MARKET
5. CASE STUDIES IN PROTEOMIC PLATFORMS FOR PHARMACEUTICAL R&D
6. DRUG DISCOVERY PIPELINE ENGAGING PROTEOMICS
7. FUTURE OUTLOOK FOR PROTEOMICS MARKET
8. FUTURE DIRECTIONS IN PROTEOMICS
9. COMPANY PROFILES
10. LESSONS LEARNED AND EMERGING OPPORTUNITIES
11.SUMMARY
APPENDIX A - LISTING OF PROTEOMICS VENDORS FOR ORDER OR INQUIRY, PLEASE CLICK "ORDER / INQUIRY FORM" |